Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.45 |
| ▸ | HSD17B3 | P37058 | 11/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15606230 | 0.95 | HSD17B3 (0.47) | NOTUMHSD17B3KDM4EHTTSMN1; SMN2 | |
| SCHEMBL17903051 | 0.91 | SMN1; SMN2 (0.49) | NOTUMHSD17B3KDM4EHTTSMN1; SMN2 | |
| SCHEMBL17469576 | 0.89 | NOTUM (0.44) | NOTUMHSD17B3KDM4EHTTSMN1; SMN2 | |
| SCHEMBL21602797 | 0.87 | SMN1; SMN2 (0.38) | NOTUMHSD17B3KDM4EHTTSMN1; SMN2 | |
| SCHEMBL16204540 | 0.86 | NOTUM (0.48) | NOTUMHSD17B3KDM4EHTTSMN1; SMN2 | |
| SCHEMBL14315405 | 0.86 | KDM4E (0.49) | NOTUMHSD17B3KDM4EHTTSMN1; SMN2 | |
| SCHEMBL17469577 | 0.85 | HSD17B3 (0.46) | NOTUMHSD17B3KDM4EHTTSMN1; SMN2 | |
| SCHEMBL23695165 | 0.84 | NOTUM (0.38) | NOTUMHSD17B3KDM4EHTTSMN1; SMN2 | |
| SCHEMBL24701748 | 0.84 | KDM4E (0.37) | NOTUMHSD17B3KDM4EHTTSMN1; SMN2 | |
| SCHEMBL25015342 | 0.83 | NOTUM (0.47) | NOTUMHSD17B3KDM4EHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399356-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-14 | — | — | US | disclosed |
| US-11725024-B2 | Antibody drug conjugates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-15 | — | — | US | disclosed |
| WO-2021034853-A1 | ATTACHING NUCLEOTIDES TO A POLYNUCLEOTIDE WITH A POLYMERASE | ILLUMINA, INC. (US) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399356-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | NOTUM 4371/4885HSD17B3 4131/4885KDM4E 2002/4885 |
| US-11725024-B2 | Antibody drug conjugates | STING1, CGAS, TBK1 | NOTUM 4371/4885HSD17B3 4131/4885KDM4E 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.